Investor Presentation January 2022

CooperCompanies Fiscal 2022 financial guidance EPS Sales Total FY22 Guidance* Growth vs. FY21 $3,032 $3,090 6% - 8% CC CooperVision $2,225 - $2,267 6% - 8% CC CooperSurgical $807 - $823 6% - 8% CC Non-GAAP $13.60 - $14.00 9.5% 12.5% cc Note: Sales $ in millions; cc means constant currency; Cooper Companies Non-GAAP and cc - Refer to earnings release for definitions and reconciliation of results; *Guidance as initiated 12/2/21. FY22 guidance does not include the Generate Life Sciences acquisition closed 12/17/21. 5

View entire presentation